A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

Movement Disorders

Volumn 23, Issue 15, 2008, Pages 2194-2201

  Olanow, C Warren ^a   Hauser, Robert A ^b   Jankovic, Joseph ^c   Langston, William ^d   Lang, Anthony ^e   Poewe, Werner ^f   Tolosa, Eduardo ^g   Stocchi, Fabrizio ^h   Melamed, Eldad ⁱ   Eyal, Eli ^j   Rascol, Olivier ^k  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d PARKINSON S INSTITUTE   (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g HOSPITAL CLÍNIC   (Spain)

^h IRCCS SAN RAFFAELE PISANA   (Italy)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j TEVA PHARMACEUTICALS   (Israel)

^k INSERM   (France)

more..

Author keywords

Delayed start design; Disease modification; Neuroprotection; Parkinson's disease; Rasagiline

Indexed keywords

PLACEBO; RASAGILINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED START STUDY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 61449173973     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22218     Document Type: Article

References (56)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):1-88.
2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-1598.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine de.ciency in Parkinson's disease. Ann Neurol 2004;55: 761-765.
5. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
6. Braak H, Tredici KD, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
7. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-307.
8. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291: 358-364.
9. Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 2006; 66(10Suppl 4):S69-S79.
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59: 1937-1943.
11. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61:561-566.
12. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62: 241-248.
13. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
14. Youdim MBH, Gross A, Finberg JPM. Rasagiline N-propargyl-1 R(1)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;32:500-506.
15. Boulton AA. Symptomatic and neuroprotective properties of the aliphatic propargylamines. Mech Ageing Dev 1999;111:201-209.
16. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000;116:181-191.
17. Maruyama W, Akao Y, Carrillo M, Kitani K, Youdium M, Naoi M. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002;245:675-682.
18. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MBH. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999;80:495-499.
19. Maruyama W, Akao Y, Youdim MBH, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan. J. Neural Transm 2000;60(Suppl): 171-186.
20. Maruyama W, Youdim MBH, Naoi M. Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan. Ann N Y Acad Sci 2000;939:320-329.
21. Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an antiparkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001;78:727-735.
22. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effects of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004;187:455-459.
23. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neuro-rescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007;25:35-44.
24. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999;366:127-135.
25. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia. J Neural Transm 1999;106:593-606.
26. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004;251:1080-1084.
27. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-515.
28. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002;301:753-764.
29. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm 2001;108:909-923.
30. Bonneh-Barkay D, Ziv N, Finberg JPM. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology 2005;48:406-416.
31. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. An antisense oligonucleotide to glyderaldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996;278:447-454.
32. Sawa A, Khan AA, Hester LD, Snyder SH. Glyderaldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuronal cell death. Proc Natl Acad Sci USA 1997;94:11669-11674.
33. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000; 57:2-12.
34. Akao Y, Maruyama W, Yi H, Shanoto-Nagai M, Youdim M, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326: 105-108.
35. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002;82: 913-23.
36. Youdim MBH, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti Alzheimer drug, TV3326, [(N-Propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 2002;21:555-573.
37. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004; 18:1471-1473.
38. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
39. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's Disease act by symptomatic or protective mechanisms? Neurology 1991;42:41-48.
40. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777.
41. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 2000;60:197-214.
42. Andringa G, van Oosten RV, Unger W, et al. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 2000;12: 3033-3043.
43. Andringa G, Eshuis S, Perentes E. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis 2003;14:205-217.
44. Olanow CW, Schapira AH, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5:1013-1020.
45. Shoulson I, Oakes D, Fahn S, et al. The impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension. Ann Neurol 2002;51: 604-612.
46. Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
47. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
48. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
49. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997;11(Suppl 5):S10-S21; discussion S37-S39.
50. Hochberg Y. A sharper bonferroni procedure for multiple significance testing. Biometrika 1988;75:800-802.
51. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
52. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Neurology 2005;64 (Suppl 1):A107.
53. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
54. Rascol O, Brooks DJ, Korczyn AD, et al. A five year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
55. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 2000;284:231-238.
56. Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the L-dopa study. N Eng J Med 2004;351:2498-2508.